Novartis Seeks Eye Care Leadership With Full, $50 Billion Alcon Takeover
This article was originally published in The Gray Sheet
Executive Summary
In a strong sign of Novartis' long-term commitment to ophthalmology, the firm announced Jan. 4 that it would exercise its option to purchase Nestlé's remaining 52% stake in eye-care group Alcon for $28.1 billion and separately pursue a buyout of the 23% of shares owned by independent stockholders
You may also be interested in...
With 100% Alcon Ownership, Novartis Forms New Eye Care Unit
Novartis will create a new eye care division – representing the fifth growth platform in its health care portfolio – after acquiring full ownership of ophthalmology specialist Alcon.
With 100% Alcon Ownership, Novartis Forms New Eye Care Unit
Novartis will create a new eye care division – representing the fifth growth platform in its health care portfolio – after acquiring full ownership of ophthalmology specialist Alcon.
As Alcon Shareholders Fight Back, Will Novartis Sweeten Its Merger Offer?
Independent Alcon shareholders have been holding out for months for a buyout offer from Novartis that is closer to what the latter firm is paying for the majority of the company